Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the european study: Molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD)

Blood

Volumn 111, Issue 10, 2008, Pages 4979-4985

  Haberichter, Sandra L ^a,b,c   Castaman, Giancarlo ^d   Budde, Ulrich ^e   Peake, Ian ^f   Goodeve, Anne ^f   Rodeghiero, Francesco ^d   Federici, Augusto B ^g   Batlle, Javier ^h   Meyer, Dominique ⁱ   Mazurier, Claudine ^j   Goudemand, Jenny ^k   Eikenboom, Jeroen ^l   Schneppenheim, Reinhard ^m   Ingerslev, Jorgen ⁿ   Vorlova, Zdena ^o   Habart, David ^o   Holmberg, Lars ^p   Lethagen, Stefan ^p   Pasi, John ^q   Hill, Frank G H ^r   Montgomery, Robert R ^a,b,c   more..

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Children's Hospital of Wisconsin   (United States)

^c BLOOD RESEARCH INSTITUTE   (United States)

^d SAN BORTOLO HOSPITAL   (Italy)

^e Coagulation Laboratory   (Germany)

^f UNIVERSITY OF SHEFFIELD   (United Kingdom)

^g UNIVERSITY OF MILAN   (Italy)

^h Hospital Teresa Herrera   (Spain)

ⁱ INSERM   (France)

^j Laboratoire Francais du Fractionnement et des Biotechnologies   (France)

^k UNIV LILLE   (France)

^l LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^m UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

ⁿ AARHUS UNIVERSITY HOSPITAL   (Denmark)

^o INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^p LUND UNIVERSITY   (Sweden)

^q QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^r BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DESMOPRESSIN; VON WILLEBRAND FACTOR; ARGIPRESSIN[1 DEAMINO]; BIOLOGICAL MARKER; PROTEIN PRECURSOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; GENE MUTATION; HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STEADY STATE; SURVIVAL RATE; VON WILLEBRAND DISEASE; BLOOD; CLINICAL TRIAL; EUROPE; HALF LIFE TIME; MORTALITY; MULTICENTER STUDY; MUTATION; PREDICTION AND FORECASTING; SURVIVAL; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; DEAMINO ARGININE VASOPRESSIN; EUROPE; HALF-LIFE; HUMANS; MUTATION; PREDICTIVE VALUE OF TESTS; PROTEIN PRECURSORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 46749133213     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-09-110940     Document Type: Article

References (38)

1. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395- 424.
2. Verweij CL, Diergaarde PJ, Hart M, Pannekoek H. Full-length von Willebrand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit [published erratum appears in EMBO J. 1986;5:3074]. EMBO J. 1986;5:1839-1847.
3. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol. 1990;6:217-246.
4. Vischer UM, Wagner DD. von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies. Blood. 1994;83:3536-3544.
5. Haberichter SL, Fahs SA, MontgomeryRR. Von Willebrand factor storage and multimerization: 2 independent intracellular processes. Blood. 2000; 96:1808-1815.
6. Wagner DD, Olmsted JB, Marder VJ. Immunolo-calization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol. 1982;95:355-360.
7. MontgomeryRR, Zimmerman TS. von Willebrand's disease antigen, II: a new plasma and platelet antigen deficient in severe von Willebrand's disease. J Clin Invest. 1978;61:1498-1507.
8. van Mourik JA, Boertjes R, Huisveld IA, et al. von Willebrand factor propeptide in vascular disorders: A tool to distinguish between acute and chronic endothelial cell perturbation. Blood. 1999; 94:179-185.
9. Borchiellini A, Fijnvandraat K, ten Cate JW, et al. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8- D-arginine vasopressin in humans. Blood. 1996; 88:2951-2958.
10. Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4:2103-2114.
11. Eikenboom JC, Matsushita T, Reitsma PH, et al. Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor. Blood. 1996;88:2433-2441.
12. Cumming A, Grundy P, Keeney S, et al. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Wille- brand disease. Thromb Haemost. 2006;96:630- 641.
13. Castaman G, Eikenboom JC, Missiaglia E, Ro- deghiero F. Autosomal dominant type 1 von will- ebrand disease due to G3639T mutation (C1130F) in exon 26 of von Willebrand factor gene: description of five Italian families and evidence for a founder effect. Br J Haematol. 2000; 108:876-879.
14. O'Brien LA, James PD, Othman M, et al. Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease. Blood. 2003;102: 549-557.
15. Allen S, Abuzenadah AM, Hinks J, et al. A novel von Willebrand disease-causing mutation (Arg273Trp) in the von Willebrand factor propep- tide that results in defective multimerization and secretion. Blood. 2000;96:560-568.
16. Castaman G, Eikenboom JC, Bertina RM, Ro- deghiero F. Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation. Thromb Haemost. 1999;82:1065-1070.
17. Goodeve A, Eikenboom J, Castaman G, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MC- MDM-1VWD). Blood. 2007;109:112-121.
18. James PD, Notley C, Hegadorn C, et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood. 2007;109:145-154.
19. Casana P, Martinez F, Haya S, Espinos C, Aznar JA. Significant linkage and non-linkage of type 1 von Willebrand disease to the von Willebrand factor gene. Br J Haematol. 2001;115:692-700.
20. Lanke E, Johansson AM, Hallden C, Lethagen S. Genetic analysis of 31 Swedish type 1 von Wille- brand disease families reveals incomplete linkage to the von Willebrand factor gene and a high frequency of a certain disease haplotype. J Thromb Haemost. 2005;3:2656-2663.
21. Bodo I, Katsumi A, Tuley EA, et al. Type 1 von Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of het- erodimers: a possible general mechanism for dominant mutations of oligomeric proteins. Blood. 2001;98:2973-2979.
22. Casonato A, Pontara E, Sartorello F, et al. Reduced von Willebrand factor survival in type Vicenzavon Willebrand disease. Blood. 2002;99: 180-184.
23. Schooten CJ, Tjernberg P, Westein E, et al. Cysteine-mutations in von Willebrand factor associated with increased clearance. J Thromb Haemost. 2005;3:2228-2237.
24. Mannucci PM, Lombardi R, Castaman G, et al. von Willebrand disease "Vicenza" with larger-than-normal (supranormal) von Willebrand factor multimers. Blood. 1988;71:65-70.
25. Haberichter SL, Balistreri M, Christopherson P, et al. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Wil-
26. lebrand disease with decreased VWF survival. Blood. 2006;108:3344-3351.
27. Eikenboom J, Van M, V, Putter H, et al. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost. 2006;4:774-782.
28. Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost. 2006;4:766-773.
29. Federici AB, Mazurier C, Berntorp E, et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood. 2004;103:2032-2038.
30. Schneppenheim R, Plendl H, Budde U. Luminography: an alternative assay for detection of von Willebrand factor multimers. Thromb Haemost. 1988;60:133-136.
31. Brown SA, Eldridge A, Collins PW, Bowen DJ. Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process? J Thromb Haemost. 2003;1:1714-1717.
32. Lenting PJ, Westein E, Terraube V, et al. An experimental model to study the in vivo survival of von Willebrand factor: basic aspects and application to the R1205H mutation. J Biol Chem. 2004; 279:12102-12109.
33. Castaman G, Lethagen S, Federici AB, et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood. 2008;111:3531-3539.
34. Schneppenheim R, Federici AB, Budde U, et al. Von Willebrand Disease type 2M "Vicenza" in Italian and German patients: identification of the first candidate mutation (G3864A; R1205H) in 8 families. Thromb Haemost. 2000;83:136-140.
35. Lyons SE, Bruck ME, Bowie EJ, Ginsburg D. Impaired intracellular transport produced by a subset of type IIAvon Willebrand disease mutations. J Biol Chem. 1992;267:4424-4430.
36. Castaman G, Missiaglia E, Federici AB, Schnep- penheim R, Rodeghiero F. An additional unique candidate mutation (G2470A; M740I) in the original families with von Willebrand disease type 2 M Vicenzaand the G3864A(R1205H) mutation. Thromb Haemost. 2000;84:350-351.
37. Mannucci PM, Lombardi R, Bader R, et al. Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Wille- brand factor. Blood. 1985;66:796-802.
38. Mannucci PM. Platelet von Willebrand factor in inherited and acquired bleeding disorders. Proc Natl Acad Sci U S A. 1995;92:2428-2432.